Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.74 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.74 |
| ▸ | CTSK | P43235 | 15/20 | 0.72 |
| ▸ | CTSS | P25774 | 6/20 | 0.70 |
| ▸ | CTSL | P07711 | 2/20 | 0.70 |
| ▸ | CTSB | P07858 | 1/20 | 0.70 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9115066 | 0.95 | CAPN1 (0.80) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL13870521 | 0.88 | CAPN1 (0.76) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL20542843 | 0.88 | CAPN1 (0.76) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL20542841 | 0.88 | CAPN1 (0.76) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL29052549 | 0.87 | CTSK (0.77) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL29052552 | 0.87 | CTSK (0.77) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL14067668 | 0.87 | CTSK (0.77) | CAPN1CAPN2CTSKCTSSCTSL | |
| Hydrochloric Acid SCHEMBL10586713 | 0.85 | CTSK (0.68) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL7137850 | 0.85 | CAPN1 (0.68) | CAPN1CAPN2CTSKCTSSCTSL | |
| SCHEMBL2670566 | 0.85 | CAPN1 (0.68) | CAPN1CAPN2CTSKCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | CAPN1 2884/4885CAPN2 3914/4885CTSK 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.